Carsgen-B (02171): Results from Kailimei® Study Presented at 2026 ESMO Annual Meeting

Stock News10-26 08:18

According to an announcement from Carsgen-B (02171), preliminary results from a clinical trial (CT041-CG4010, NCT06857786) conducted in China evaluating Kailimei® (satri-cel injection, product code: CT041, an autologous CAR-T cell therapy candidate targeting Claudin18.2) as consolidation therapy following adjuvant treatment in patients with Claudin18.2-positive gastric/gastroesophageal junction cancer after radical resection were presented as a poster at the 2026 European Society for Medical Oncology (ESMO) Annual Meeting on Sunday, October 25, 2026, from 12:00 to 12:45 Central European Summer Time (CEST).

The poster presented at the 2026 ESMO Annual Meeting was titled "Satricabtagene autoleucel (satri-cel) as consolidation therapy following adjuvant treatment for locally advanced gastric or gastroesophageal junction cancer (G/GEJC): preliminary results from a phase Ib trial."

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment